NRG
CRL icon

Nemes Rush Group’s Charles River Laboratories CRL Stock Holding History

Nemes Rush Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$863 Buy
+5
New +$927 ﹤0.01% 842
2025
Q4 		– Sell
-2
Closed -$313 – 994
2025
Q3 		$313 Hold
2
– – ﹤0.01% 665
2025
Q2 		$303 Hold
2
– – ﹤0.01% 701
2025
Q1 		$301 Hold
2
– – ﹤0.01% 689
2024
Q4 		$369 Buy
+2
New +$385 ﹤0.01% 707

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Nemes Rush Group's CRL Position: Q1 2026 in Review

Nemes Rush Group opened a new position in Charles River Laboratories (CRL) in Q1 2026: 5 shares worth $863. The stake represents ﹤0.01% of the portfolio and ranks #842 among its holdings. This is a return to the name: Nemes Rush Group previously reported a position in CRL as recently as Q3 2025.

Nemes Rush Group first reported a position in CRL in Q4 2024 and has held it in 5 quarters since. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Nemes Rush Group held 5 shares of Charles River Laboratories worth $863 as of Q1 2026.
  • Charles River Laboratories was a new Nemes Rush Group position in Q1 2026.
  • Charles River Laboratories made up ﹤0.01% of Nemes Rush Group's portfolio in Q1 2026, its #842 holding.
  • Nemes Rush Group first reported a position in Charles River Laboratories in Q4 2024 and has held it in 5 quarters since.
  • 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.